Background and Vision
Cognixion, headquartered in Santa Barbara, California, is developing a noninvasive brain‑computer interface (BCI) that translates brain signals into digital commands. Unlike implant‑based systems such as Elon Musk’s Neuralink, Cognixion’s approach relies on a wearable headband with six electroencephalographic (EEG) sensors that capture activity from the visual and parietal cortex. The company’s CEO, Andreas Forsland, founded Cognixion after witnessing his mother’s inability to speak while fully conscious in an intensive‑care setting, prompting a focus on communication solutions for people with speech motor disabilities.
Integration with Apple Vision Pro
The new trial integrates Cognixion’s BCI with Apple’s Vision Pro mixed‑reality headset. Apple recently introduced a protocol allowing users with severe mobility impairments to control iPhone, iPad, and Vision Pro devices without physical movement. Cognixion replaces Apple’s standard headband with its own sensor‑rich version, while the Vision Pro provides a full suite of apps, an app store, and advanced eye‑tracking capabilities. A neural computing pack worn at the hip processes the brain‑wave data outside the headset.
How the System Works
The BCI detects visual fixation signals—moments when a user maintains gaze on a specific object—to enable selection from on‑screen menus using mental attention alone. In addition to brain‑wave detection, the system can incorporate eye‑tracking and head‑movement inputs for users who retain those abilities. Cognixion’s software leverages generative AI models that are trained on each individual’s speech patterns, humor, and written history, creating a personalized “user proxy.” This AI generates suggested phrases that the user can select or compose, allowing communication at a rate approaching normal conversation speed.
Clinical Trial Design
The trial will enroll up to ten participants in the United States who have speech impairments stemming from paralysis due to spinal‑cord injury, stroke, traumatic brain injury, or amyotrophic lateral sclerosis (ALS). Participants will use the system for a few hours a day, several times a week, mirroring a prior study with Cognixion’s purpose‑built Axon‑R headset that demonstrated comfortable, regular use. The company plans a larger pivotal trial involving around 30 patients to gather data for potential FDA clearance, which would assess user‑friendliness and quality‑of‑life improvements.
Industry Context and Expert Views
Other BCI firms, including Synchron, have also explored Vision Pro integration, though Synchron’s approach involves an implant placed in a blood vessel adjacent to the brain. UCLA BCI researcher Jonathan Kao, who is not affiliated with Cognixion, acknowledges the promise of noninvasive BCIs but notes that signal quality remains weaker and noisier compared with invasive devices, presenting challenges for rapid and reliable decoding. Kao suggests that AI copilots, like the one Cognixion is developing, could bridge performance gaps and enable broader adoption of non‑surgical BCI solutions.
Potential Impact
Cognixion’s noninvasive strategy aims to reduce the risk and increase accessibility of BCI technology, positioning the Vision Pro as a platform that could reach a larger patient population faster than surgically implanted alternatives. By combining EEG‑based brain‑wave detection with advanced AI personalization, the company hopes to provide a practical communication tool that improves daily life for individuals with severe speech motor disabilities.
Este artículo fue escrito con la asistencia de IA.
News Factory SEO te ayuda a automatizar contenido de noticias para tu sitio.